Pacific Biosciences beats by $0.08, beats on revs (PACB) 4.90 -0.03 : Reports Q4 (Dec) loss of $0.42 per share, $0.08 better than the Capital IQ Consensus Estimate of ($0.50); revenues rose to $12.4 mln from $280K in 4Q10 vs the $10.35 mln consensus. Gross profit for the fourth quarter totaled $1.5 million, resulting in a gross margin of 12%, compared to gross profit for the third quarter 2011 of $3.3 million and a gross margin of 32%. Gross margin for both the fourth and third quarters reflect the margin positive impact of significant instrument component costs that were expensed during prior periods. During development, costs relating to instrument components and manufacturing costs were expensed until commercial production started.
Market Data 
Markets 
AI
